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We have come a long way in our understanding of
inflammation since the days of Celsus (about 30 BC to 
38 AD) and his original description of the inflammatory
response in terms of cardinal signs — heat, redness,
swelling and pain. Dotted throughout its colourful
history, inflammation research has had innumerable
individuals who have described many of the mecha-
nisms associated with tissue injury. Among these are
Lewis (1881–1945), who described the Triple Response;
Cohnheim and Samuel (late 1800s), who reported on
leukocyte emigration and vascular permeability; and
Metchnikoff (1845–1916), who described phagocytosis,
to name but a few1. However, even until the mid-
twentieth century our understanding of the chemical
mediators that bring about these events — in particular,
changes that lead to VASCULAR LEAKAGE, pain and cell accu-
mulation — was lacking. Indeed, Wilhelm, writing in
the mid-1960s, commented that “Half a century of
work on the identification of substances increasing
vascular permeability and the other vascular events in
the inflammatory process has resulted in little reliable
information concerning relevant chemical mediators”1.
The subsequent 40 years of research have made up for
this shortfall by revealing many of the factors that we
now know propagate the initial response to tissue injury
(BOX 1). However, once the inflammatory leukocyte and
the exudate have entered the inflammatory site and
neutralized the inciting agent, they must be eliminated
and cleared in a NON-PHLOGISTIC manner. This is acute
inflammatory resolution, a burgeoning area of inflam-
mation research that might help to understand the
aetiology of chronic inflammation. Like Wilhelm and
colleagues in the 1960s, who lamented the lack of
understanding of the mediators that drive acute
inflammation, we stand now in the new millennium
knowing little of what switches it off. In much the
same way as pharmacologists developed drugs based
on blocking what initiates and drives inflammation,
perhaps now we can develop new anti-inflammatory
drugs based on mimicking those molecules that
resolve the problem.
What is inflammatory resolution?
It is a popular misconception that once the inflamma-
tory response has neutralized an injurious stimulus,
inflammation somehow fizzles out, possibly from pro-
inflammatory mediator catabolism. On the contrary, the
resolution of acute inflammation is a highly coordi-
nated and active process that is controlled by endo-
genous ‘pro-resolving’ mediators. These factors switch
off leukocyte trafficking to the inflamed site, reverse
vasodilation and vascular permeability, and bring
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The process of the escape of
plasma and plasma proteins,
along with white blood cells, from
the vessel is known as
exudation. This inflammatory
exudate accounts for an increase
in the volume of interstitial fluid
(oedema) and tissue swelling at
the local site of injury.
NON-PHLOGISTIC
Non-inflammatory. This term 
is used to describe the clearance
of leukocytes in a manner that
does not elicit an inflammatory
response.
NF-κB
(Nuclear factor of κB). A group
of sequence-specific
transcription factors that are
best known as key regulators 
of the innate and adaptive
inflammatory responses, cell
survival and ancogenesis. In
mammals, NF-κB consists of
five structurally related and
functionally conserved
proteins: RELA (p65), RELB,
c-REL, NF-κB1 (p105 and p50)
and NF-κB2 (p100 and p52).
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of an immune response to an endogenous antigen
(autoimmunity)4–7. This review will not consider
aspects of wound healing or chronic inflammation
but will focus on the mediators and mechanisms that
regulate the fate of inflammatory leukocytes during
the resolution of acute inflammation.
Why develop drugs based on resolution?
A range of therapies exist for the treatment of inflam-
mation-driven diseases such as asthma, rheumatoid
arthritis, psoriatic arthritis, systemic lupus erythemato-
sus, Crohn’s disease, multiple sclerosis and systemic
vasculitis. However, such therapeutics have undesirable
side effects. For instance, steroids can cause osteo-
porosis8 and impair wound healing9, whereas novel
selective inducible cyclooxygenase (COX)2 inhibitors
might reduce protective vascular prostacyclin synthesis,
leading to an increased risk of thrombosis10. Indeed, expe-
rience with tumour necrosis factor-α (TNF-α)-neutraliz-
ing therapy has also revealed several complications11.
Clinical studies indicate that TNF-α-neutralizing
therapy should not be given to patients with cardiac
failure or a history of demyelinating disease. In addi-
tion, increased infection rates can occur, especially the
activation of latent tuberculosis, although other
opportunistic infections such as listeriosis, pneumo-
nia and aspergillosis have also been reported. These
unwanted side effects stem from the inhibition of
essential endogenous factors that have a role in normal
physiology or, in the case of anti-TNF-α, by dampening
down the host’s ability to adequately deal with infec-
tion, given that the innate inflammatory response is a
beneficial defensive event. Our view is that detailed
characterization of the biochemical pathways leading
to resolution might lead to the identification of novel
targets that can be exploited for innovative anti-
inflammatory drug discovery. We foresee that novel
compounds based on the mechanism of action of a
given pro-resolving mediator will be modulatory in
their action and likely to produce a lower burden of
side effects.
Mediators and mechanisms of resolution
Studies on the resolution of acute inflammation have
already revealed novel mediators with potent anti-
inflammatory properties. Determining their basic struc-
ture and function might help in the development of
unique anti-inflammatory therapeutics. So far, these
pro-resolving mediators have been shown to exert
powerful anti-inflammatory effects in various experi-
mental models of inflammatory diseases. Of these,
lipid-mediator derivatives of the COX2 and lipoxy-
genase (LOX)/LOX interaction pathways of arachidonic
acid, eicosapentaenoic acid (EPA) and docosahexa-
enoic acid (DHA) metabolism, as well as inducible
haem-oxygenase (HO-1), will be described in this
review. We will also discuss the fate of inflammatory
leukocytes after their job is done (apoptosis), reveal a
virtuous side to nuclear factor (NF)-κB and discuss how
old workhorses of inflammation (glucocorticoids and
annexins) cross paths with the new (lipoxins).
about the safe disposal of inflammatory leukocytes,
exudate and fibrin, thereby leading to the restoration
of the inflamed tissue to its prior physiological func-
tion. Importantly, successful resolution will limit
excessive tissue injury and give little opportunity for
the development of chronic, immune-mediated
inflammation2. However, if the host is unable to neu-
tralize the injurious agent and/or there is a failure of
endogenous pro-resolving mediators to invoke resolu-
tion, then acute inflammation might perpetuate,
resulting in varying degrees of tissue injury. If tissue
injury is mild, necrotic parenchymal cells will be
replaced by new cells of the same type in a process
known as regeneration. If, however, tissue damage is
extensive, or when fibrin is not rapidly cleared after
acute inflammation, the process of healing is by repair.
This involves the in-growth from the surrounding
connective tissue of an initially vascular tissue contain-
ing capillary loops, fibroblasts and leukocytes, and is
known as granulation tissue. With time, the fibroblasts
lay down collagen and the capillaries disappear, leaving
an avascular area of fibrosis or scar. Repair by granula-
tion and fibrosis occurs in many parts of the body
where a deposit of clot, exudate or dead tissue occurs
and is given the general name of organization3 (FIG. 1).
Undoubtedly, this is also a form of inflammatory reso-
lution associated with tissue damage. As in rheumatoid
arthritis and asthma, for example, there will be con-
tinuous or repeated bouts of acute inflammation,
resulting in ongoing tissue damage. Attempts at
wound healing would result in granulomatous tissue
formation, angiogenesis, fibrosis and scar formation, all
occurring concurrently2. This is chronic inflammation
and might be defined as a continuous inflammatory
disease state that could be driven by the development
Box 1 | Mediators of the acute inflammatory response
Mediators known to drive the acute inflammatory response
• The clotting system products (plasmin, fibrinopeptides)
• Fibrinolytic system products (fibrin)
• Kinins (bradykinin)
• Vasoactive amines (histamine and 5-hydroxytryptamine)
• Substance P
• Complement system by-products 




• Oxygen-derived free radicals 
• Nitric oxide




• Mediators of apoptosis (caspases, CD44, etc.)
• Annexin-1
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Figure 1 | Scheme of events depicting the various consequences to acute
inflammation. In the first instance, inflammatory leukocytes migrate to the inflamed 
site or area of tissue damage, with PMNs or eosinophils being the first cell types at the 
scene (a). Although in some circumstances PMNs are cleared from the inflamed site by
returning to the circulation, the most common fate of PMNs is apoptosis, after which 
they are phagocytosed by newly migrated macrophages (macrophages containing effete
leukocytes are called Reiter cells). Macrophages, in turn, might apoptose locally or be
cleared by lymphatic drainage (b), thereby allowing this acute inflammatory response to
resolve and the inflamed tissue to return to its normal physiological function (c). Invariably,
however, there is some evidence of parenchymal tissue damage (d), with some cells 
dying by necrosis but, in turn, being replaced by local tissue regeneration and some
evidence of residual tissue scarring (e). If, however, the surrounding tissue damage is
extensive, the process of healing is by repair. This involves the in-growth from the
surrounding connective tissue of an initially vascular tissue containing endothelial cells,
fibroblasts, myofibroblasts and macrophages, and is known as granulation tissue (f). 
After some time, the number of macrophages and myofibroblasts decline. Eventually,
fibroblasts lay down collagen and the capillaries disappear, leaving a dense avascular,
hypocellular extracellular matrix (g).
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to exert its effects through PPARγ-dependent as well as 
-independent mechanisms16, resulting in the suppression
of various pro-inflammatory signalling pathways.
These include pathways that operate through NF-κB,
AP1 and SIGNAL TRANSDUCERS AND ACTIVATORS OF TRANSCRIPTION
(STATs)14,15,17–19, as well as the suppression of inducible
nitric oxide synthase, interleukin (IL)-1β, TNF-α and
IL-12 in macrophages14,20, microglial cells21,22 and den-
dritic cells23. 15d-PGJ
2
also preferentially inhibits mono-
cyte rather than POLYMORPHONUCLEAR LEUKOCYTE (PMN)
trafficking through the differential regulation of cell-
adhesion molecule and chemokine expression24–27,
indicating that cyclopentenone PGs (cyPGs) do not
control the onset phase of acute inflammation, in which
PMNs predominate, but tightly regulate the chronicity of
the inflammatory response. In support of this, we have




is a major product from a COX-
catalysed reaction in a variety of tissues and cells,
including those of the immune system, such as mast
cells, platelets, T cells, dendritic cells and macrophages.
PGD
2
has significanteffects on a number of biological
processes, including inhibition of plateletaggregation,
vascular and nonvascular smooth-muscle relaxation, as
well as sleep–wake regulation and inflammation12. PGD
2
undergoes dehydration in vivo and in vitro to yield












which are characterized by the presence of a reactive
α,β-unsaturated ketone in the cyclopentenone ring13
(FIG. 2). Although 15d-PGJ
2
was initially identified as a
high-affinity natural ligand for PEROXISOME PROLIFERATOR-
ACTIVATED RECEPTOR gamma (PPARγ)14,15, it is now thought
PEROXISOME PROLIFERATOR-
ACTIVATED RECEPTORS
(PPARs). Members of the
nuclear receptor family that
regulate the transcription of
genes involved in lipid and
lipoprotein metabolism, glucose
and energy homeostasis, as well
as cellular differentiation. They
consist of three isotypes: alpha
(NR1C1), gamma (NR1C3) and






(STAT) proteins are intracellular




(PMNs). Discovered by Paul
Ehrlich who used contemporary
fixing and staining techniques to
identify the lobulated nucleus
and the granules that typify cells
that we now classify as
eosinophils, basophils and
neutrophils. In the context of







































Figure 2 | Arachidonic metabolism by COX, as well as the LOX and cytochrome p450 family of enzymes. Arachidonic acid
is released by either cytosolic, secretory or calcium-independent phospholipase A2. The phospholipase A2 involved is cell-type- and
stimulus-specific. Liberated arachidonic acid is metabolized by cyclooxygenase (COX)1 or COX2 to PGG2 and then PGH2. PGH2
serves as a substrate for a series of downstream synthases to give rise to the prostaglandins. For PGD2 synthesis, PGH2 is
metabolized by haematopoietic prostaglandin D2 synthase. PGD2, in turn, is non-enzymically broken down to the cyPGs. PGD2,
prostaglandin D2; PGG2, prostaglandin G2; PGH2, prostaglandin H2.
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(cDNA) are introduced to mice bearing bleomycin-
induced lung injury, significantly reduced lung oedema,
leukocyte infiltration in bronchoalveolar lavage fluid
and pulmonary collagen content is observed, in addition
to prolonging the lifespan of the transfected mice37.
These results, as well as those showing a protective role
for 15d-PGJ
2
in models of ischaemia reperfusion
injury38,39, inflammatory bowel disease38, adjuvant-
induced arthritis40 and experimental autoimmune
encephalomyelitis41, provide support for 15d-PGJ
2
as a
novel therapeutic agent against inflammatory diseases.
PGD
2
and the cyPGs might contribute to the resolu-
tion of inflammation through various mechanisms
that include the inhibition of the expression of pro-
inflammatory genes, the induction of apoptosis in
activated macrophages and myofibroblasts, and the acti-
vation of PPARγ. However, stable therapeutics based on
PGD
2
and its metabolites might not be a panacea for all
inflammatory processes. For instance, in the lung there
is mounting evidence that PGD
2
might contribute sig-
nificantly to the symptoms and pathogenesis associated
with asthma42,43, indicating that although such putative
endogenous PGs might be protective at one site of tissue
injury, it might be detrimental at another, reflecting
differing organ-specific aetiologies of disease processes
in terms of onset and resolution.
Effect of haem oxygenase induction
There is still much debate over the differential effects of
15d-PGJ
2 
on pro-inflammatory cytokine synthesis.
However, a closer look at the literature reveals that this
disparity arises from the concentrations of 15d-PGJ
2
(ng or µg) used on different cell types (peripheral
blood monocytes-macrophages, J774 macrophages or
A549 cells) that are stimulated differently (such as LPS,
PMA and TNF-α)14,26,44. However, one interesting
observation from these studies was the delayed but
sustained inhibition of LPS-stimulated TNF-α release
achieved by low concentration 15d-PGJ
2
(0.5 µM) on
LPS-treated J774 macrophages, whichwas attributed to
the induction of HO-1 by 15d-PGJ
2
(REF. 44). HO-1 is a
stress-inducible enzyme that catalysesthe degradation of
haem to liberate free iron, carbon monoxide, BILIVERDIN
and BILIRUBIN in mammalian cells45 and was one of the
original endogenous factors identified as playing a crucial
role in the resolution of acute pleuritis46, with current
studies indicating that HO-1 might also have a role
during the onset phase of acute inflammation by regu-
lating PMN trafficking47. 15d-PGJ
2
induction of HO-1
and its associated suppression of pro-inflammatory gene
expression is certainly consistent with its role in acute
inflammatory resolution, but the interaction between
HO-1 and 15d-PGJ
2
during this phase has yet to be
clarified. Numerous studies have since reported an
importantrole for HO-1 as a defence mechanism against
oxidative insults through the antioxidant properties of
biliverdinand bilirubin, as well as the anti-inflammatory
action of carbon monoxide48. Moreover, in mouse-to-rat
transplantation, induction of HO-1 by cobra venom
factor and cyclosporine A in endothelial and smooth-
muscle cells of cardiac xenografts prior to transplantation
This enzyme not only contributes to the onset of the
reaction through the synthesis of pro-inflammatory
PGE
2





. Moreover, we recently
identified the phospholipases (PLAs) that release arachi-
donic acid for these dual phases of eicosanoid metabo-
lism with calcium-independent PLA
2
, and to a lesser
extent secretory PLA
2
, which is necessary for the onset
phase switching to a requirement for cytosolic PLA
2
coupling to COX2 during resolution for the generation
of pro-resolving PGD
2





bring about resolution, in part, by inducing
PMN and, surprisingly, macrophage apoptosis31, albeit
a contentious issue. Indeed, of all the leukocytes,
macrophages tend to be very resistant to undergoing
programmed cell death. Yet, 15d-PGJ
2 
has previously
been reported to induce granulocyte32, macrophage33
and, more recently, myofibroblast apoptosis34. These
studies indicate that the cyPGs might not only be
important for controlling the fate of inflammatory
leukocytes during the resolution of acute inflamma-
tion, but also in preventing complications arising from
excessive tissue fibrosis and wound healing.
That 15d-PGJ
2 
has both PPARγ-dependent and 
-independent effects and that it is formed by non-
enzymic dehydration from the parent eicosanoid,
PGD
2
, makes tying down the precise contribution of
15d-PGJ
2 
to the inflammatory response problematic.
However, we can begin to get some idea about this by
examining the inflammatory response in mice that are





from its COX-derived PGH
2
pre-
cursor. Therefore, in an immune-mediated DELAYED-TYPE
HYPERSENSITIVITY reaction, mice that are deficient in
haematopoietic PGD
2
synthase showed an exaggerated
inflammatory response that failed to resolve readily.
Lymphocytes from these animals proliferated uncon-
trollably, producing a T
H
1-type cytokine profile and
showed enhanced binding or pro-inflammatory NF-κB
activity (D.W.G., J. Newson, S. Gor and P.R. Colville-
Nash, manuscript in preparation; see BOX 2). Despite
the questions surrounding the PPARγ-dependent or -
independent effects of 15d-PGJ
2
, these results are in
general agreement with those obtained from PPARγ+/–
mice with a type IV hypersensitivity reaction36. Similarly,







hypersensitivity or type IV
hypersensitivity is mediated by 
T lymphocytes and not by
antibody–antigen complexes
(arthus or type III
hypersensitivity). Typically, this
response occurs 24–72 hours
after the sensitized host is
exposed to the offending
antigen. For example, a DTH
reaction might be set up
experimentally by sensitizing to
methylated bovine serum
albumin in Freund’s complete
adjuvant and challenging 12








2 hypothesis came to
prominence in the late 1980s,
indicating that mouse T-helper
(T
H
) cells broadly express
differing cytokine profiles.
Whereas T-helper 1 (T
H
1) cells
secrete IFN-γ and TNF-α; T
H
2




CD25+CD4+ T cells exist that
produce TGF-β and IL-10,
respectively.
BILIVERDIN and BILIRUBIN
Haem catabolites with anti-
inflammatory properties due to
scavenging of free radicals.
Box 2 | Cytokines and the resolution of acute inflammation
In unpublished experiments, we found a peak in interleukin (IL)-10 and transforming
growth factor (TGF)-β1 expression during the resolving phase of acute inflammation,
indicating an important role for these cytokines in pro-resolution. We suspect that they
are synthesized by macrophages following the recognition of apoptotic
polymorphonuclear leukocytes (PMNs; see the in vitro work in REFS 81,138,140). In
addition, is was recently reported that under the control of interferon (IFN)-γ, IL-6 and
its soluble receptor controls PMN trafficking in peritoneal inflammation by suppressing
CXC and CC chemokine expression and hence further PMN recruitment146,147.
Furthermore, IL-6 and its soluble receptor promotes PMN apoptosis and clearance.
This highlights some of the early signals that might influence the longevity of PMNs in
self-limiting inflammation.
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Aspirin acetylation of COX2
Figure 3 | Biosynthesis of LXs occurs through three distinct biosynthetic pathways. a | The first is via platelet–PMN
(polymorphonuclear leukocyte) interactions, whereby 5-LOX (lipoxygenase) in PMNs metabolizes arachidonic acid to leukotriene
A4 (LXA4), which is taken up by platelets in a transcellular manner and converted by platelet 12-LOX to LXA4 (REFS 142,143). 
b | The second route of lipoxin (LX) formation is via the action of monocytes or epithelial-cell 15-LOX. Molecular oxygen is
inserted into carbon 15 of arachidonic acid, yielding 15(S)hydroperoxyeicosatetraenoic acid, which can then serve as a substrate
for PMN 5-LOX to generate 5,6-epoxytetraene. This unstable epoxide intermediate is converted to LXA4 and LXB4 by epoxide
hydrolases in leukocytes144. A final and unorthodox route for LX metabolism involves aspirin145. c | Aspirin acetylates the active
site of cyclooxygenase (COX)2, resulting not in the inhibition of COX2 enzyme activity but in the conversion of arachidonic acid
to 15(R)-hydroxyeicosatetraenoic, which when released from endothelial and epithelial cells might be transformed by leukocyte
5-LOX to generate 15-epi-LXA4 or 15-epi-LXB4.
NATURE REVIEWS | DRUG DISCOVERY VOLUME 3 | MAY 2004 | 407
R E V I E W S
Resolvins. Arachidonic acid is not the only fatty-acid
substrate that can be transformed by COXs and LOXs to
bioactive mediators with roles in anti-inflammation
and resolution. DHA and EPA — omega-3 fatty-acid
constituents of fish oils — were shown recently to be
metabolized during the resolving phase of an aspirin-
treated TNF-α-induced inflammation to potent anti-
inflammatory products, aptly named resolvins63,64 (FIG. 4).
For instance, endothelial cells expressing COX2 and
treated with aspirin convert EPA to 18R-hydroxyeicosa-
pentaenoicacid (HEPE) and 15R-HEPE. Both are sub-
sequently used by PMNs to generate separate classes of
novel trihydroxy-containing mediators that potently
inhibit human PMN transendothelial migration63.
Similarly, aspirin-acetylated COX2 converts DHA to
17R-HDHA, which is subsequently transformed by
PMNs into two sets of novel di- and trihydroxy products
that can inhibit microglial-cell cytokine expression and
ameliorate experimental models of dermal inflammation
and leukocyte accumulation in peritonitis at nanogram
doses64. Even in the absence of aspirin, human whole
blood converts DHA to 17S series resolvins as well as
novel dihydroxy-containing docosanoids. DHA-loaded
glial cells stimulated with zymosan also release
docosanoids, with these novel resolvins possessing such
potent anti-inflammatory effects as inhibiting leukocyte
trafficking in vivo and pro-inflammatory cytokine release
by stimulated human glial cells65.
Collectively, the LXs and resolvins represent novel
classes of anti-inflammatory agents that are tightly
associated with the resolution of acute inflammation
and shown to be implicated in the pathogenesis of disease
processes, including atherosclerosis66, periodontitis67,
chronic liver disease68 and asthma69. Moreover, LXs and
their analogues are proving to be highly effective thera-
peutics in a range of experimental disease models,
including immune-mediated glomerulonephritis70 and
renal ischaemia-reperfusion injury71, a range of skin
inflammatory-like diseases72 and gastritis73. Lipid media-
tors of this sort are not only natural and essential com-
ponents of acute inflammatory resolution, but show
that when applied to inflammatory disease processes are
highly effective, thereby providing the rationale for the
development of compliant and stable mimetics that tar-
get key aspects of chronic inflammation, either ongoing
or recurrent, forcing them down a revolving pathway
and into remission.
Apoptosis and phagocytosis
What is the fate of inflammatory leukocytes after they
have carried out their role? There are a number of
routes available for the efficient clearance of these
cells, including systemic re-circulation74,75, lymphatic
drainage76,77, or death by either apoptosis or necrosis
followed by phagocytosis, with apoptosis followed by
phagocytosis being considered the most desirable for
successful resolution78. It is clear that apoptosis has a fun-
damental role in almost all biological processes and there
is increasing evidence to indicate that dysregulated
apoptosis is likely to be an important factor in the patho-
genesis and progression of a number of diseases79,80.
prolongs the survival rate of these organs49. Upregulation
of HO-1 with anti-CD40L monoclonal antibody also
protects mouse allografts against transplant rejection50,
whereas induction of HO-1 by cobalt-protoporphyrin
IX protects against murine acute graft-versus-host
disease51. So, compounds that regulate HO-1 might
represent yet another strategy for the treatment of
inflammatory diseases.
The lipoxins and resolvins
Lipoxins. Transcellular metabolism of arachidonic acid
by LOX/LOX interaction pathways gives rise to the
lipoxin (LX) family of eicosanoid metabolites (FIG. 3). LXs
display selective actions on leukocytes that include
inhibition of PMN chemotaxis52, PMN adhesion to and
transmigration through endothelial cells53, as well as
PMN-mediated increases in vascular permeability54. In
contrast to their effects on PMN and eosinophils, LXs are
potent stimuli for peripheral blood monocytes, stimu-
lating monocyte chemotaxis and adherence55,56 without
causing degranulation or release of reactive oxygen
species57. In fact, LXs and their stable analogues accelerate
the resolution of allergic pleural oedema58 and enhance
phagocytosis of apoptotic PMNs by monocyte-derived
macrophages in a non-phlogistic fashion59,60, paving the





, as well as their stable analogues,
act with high affinity at a G-protein-coupled receptor,
LXA
4
receptor (ALXR; also referred to as formyl peptide
receptor-like 1 or FPRL1). FPRL1 is a member of the
family of seven transmembrane G-coupled receptors,
which has at least two other members — FPRL2 and the
formyl-Met-Leu-Phe receptor (FPR). By contrast, LXB
4
does not bind the ALXR and, although functional studies
have indicated the existence of a receptor that is activated
by LXB
4
, this receptor has not been cloned61.As with the
cyPGs, the LXs have also been identified as being
expressed during and being crucially important for the
resolution of acute inflammation. In a model of rat





as being present during the clearance of
oedema in this model62. Inhibition of their synthesis
prolonged oedema clearance, which was rescued using
stable analogues of these eicosanoids.A recent analysis of
eicosanoid synthesis in a murine dorsal AIR-POUCH MODEL
of acuteinflammation elicited by TNF-α has revealed a
switch in lipid-class metabolism reminiscent of that
found in the rat carrageenin-induced pleurisy. In
response to TNF-α, levels of leukotriene B
4
increased
rapidly, followed by PMN infiltration, which coincided
with a rise in inflammatory exudate PGE
2 
(REF. 52).
Concomitant with the eventual reduction in PMN num-
bers and PGE
2





induced a switch in lipid mediatorsynthesis





. Along with our
findings in the rat carrageenin-induced pleurisy in terms
of PG metabolism29,30, this work indicates that, in acute
inflammation, lipid-mediator biosynthesis is biphasic,
with a role for eicosanoids in the initiation as well as
termination of the inflammatory response.
AIR-POUCH MODEL
The inflation of an air pouch 
on the dorsum of mice or rats
allows for the introduction of
inflammatory stimuli to
examine either innate or
adaptive immune responses.
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b  18R: E-series resolvins
a  17R: D-series resolvins
Figure 4 | Synthesis of DHA- and EPA-derived eicosanoid resolvins. Arachidonic acid is metabolized by the aspirin-acetylated
cyclooxygenase (COX)2/lipoxygenase (LOX) interaction pathway to the epi-LXs, and substitution of arachidonic acid with ω-3 poly-
unsaturated fatty acids (such as DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid)) as substrates gives rise to the resolvins.
a | Human COX2 can convert DHA to 13-hydroxy-DHA, which switches with aspirin to 17R-HDHA. Human PMNs transformed aspirin-
acetylated COX2-derived 17R-hydroxy-DHA into two sets of novel di- and trihydroxy products; one initiated via oxygenation at carbon 7
and the other at carbon 4 (REF. 64). b | By contrast, endothelial cells that express COX2 and that are treated with aspirin will convert EPA
to 18R-hydroxyeicosapentaenoic acid and 15R-hydroxyeicosapentaenoic acid. Each can be further metabolized by PMNs to generate
separate classes of novel trihydroxy-containing mediators, including 5-series 15R-LX5 and 5,12,18R-trihydroxyeicosapentaenoic acid
63.
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One extremely active area of drug development that
targets apoptosis is the identification of small-molecule
caspase inhibitors. Caspases are a family of cysteinyl
aspartate-specific proteases that are of fundamental
importance in the initiation and execution of apoptosis,
ultimately being responsible for the dismantling of the
cell during apoptosis94,95. A number of small-molecule
inhibitors of caspases (for example, ZVAD-fmk) have
already been tested in animal models of human disease
with remarkable success. For example, specific caspase
inhibitors have been shown to be effective in preventing
or reducing the effects of ischaemia (for example, organ
failure and death) in various animal models79,96,97. These
inhibitors of apoptosis are now being tested pre-clinically
or have reached clinical trials for hepatic disease, acute
myocardial infarction and sepsis93. A good example of a
novel specific broad-spectrum caspase inhibitor that
has been successfully used pre-clinically is IDN-6556
(REF. 98). This compound, administered by a number of
routes, was shown to be potent and efficient in reducing
signs of liver damage in in vivo rodent models of liver
disease. It was shown that the compound seemed to
exert its activity by effectively inhibiting caspase
activity99. Furthermore, this drug has successfully
undergone Phase II clinical trials for liver disease in
which it was well tolerated and reduced plasma alanine
aminotransferease activity, a marker for hepatic injury,
in patients with liver impairment100. There are a number
of other drugs that are in development for inhibiting
apoptosis, but so far the most promising therapeutic
development is in the induction of apoptosis, especially
for the treatment of a number of cancers. The strategy for
inducing apoptosis has been to block powerful survival
pathways by, for example, inhibiting BCL2-mediated
survival using antisense oligonucleotides, and inter-
ference of survival pathways that are mediated by
NF-κB, phosphoinositol-3-kinase and tyrosine kinase
activation. Another strategy is to directly induce
apoptosis by engaging death-receptor pathways (such
as FASR, TNFR and TRAILR) or by other less well-
defined mechanisms93.
NF-κB
The NF-κB pathway is pivotal in the inflammatory
response by regulating the expression of pro-inflamma-
tory cytokines, chemokines and inducible enzymes101.
Furthermore, NF-κB controls the expression of anti-
apoptotic genes that might protect inflammatory leuko-
cytes from programmed cell death102, an important
determinant of inflammatory resolution. Given the cen-
tral role of this pathway in the initiation of the inflamma-
tory response and preservation of leukocyte longevity,
it seems that factors that threaten the pro-inflammatory
or anti-apoptotic status of NF-κB would hasten the
resolution of inflammation. Some insight into this was
provided by the PPARγ-independent inhibitory effects
of 15d-PGJ
2
on NF-κB activation (see BOX 3). For
example, the NF-κB pathway regulates the expression
of the anti-apoptotic protein BCL-X
L
, the promoter
activation of which is inhibited by 15d-PGJ
2
. This leads
to programmed cell death of CD28 co-stimulated
Enhanced undesirable apoptosis occurs in many
neurological diseases, such as Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease and multiple
sclerosis. Furthermore, inappropriate inflammatory
responses or dysfunctional vascular effects leading to
tissue damage with increased apoptosis have been
observed. So, there is good evidence of cell or tissue
apoptosis during myocardial infarction, stroke or sepsis.
Consequently, a therapeutic strategy to delay or inhibit
apoptosis would seem a viable option assuming that cell
specificity can be achieved.
On the other hand, there is much evidence indicat-
ing that reduced apoptosis occurs in most cancers.
Essentially, as well as uncontrolled cell division or pro-
liferation, there is an apparent failure of cancerous cells
to undergo apoptosis. It has also been proposed that in
many inflammatory diseases (for example, rheumatoid
arthritis, atopic dermatitis, Crohn’s disease, asthma
and chronic obstructive pulmonary disease) there
might be delayed apoptosis of key inflammatory cells,
thereby prolonging the functional responsiveness of
these potential histotoxic cells. A strategy to specifically
promote death of cancer cells or tissue-damaging
inflammatory cells is therefore likely to be therapeuti-
cally beneficial. However, any attempts to induce cell,
especially inflammatory-cell, apoptosis must be
matched by effective non-inflammatory clearance by
phagocytic cells (for example, macrophages)60,78,81.
Failure to remove these apoptotic cells would
undoubtedly lead to the cells becoming necrotic,
thereby increasing the potential for tissue damage
occurring. Great progress has been achieved in recent
years in the elucidation of the complex mechanisms
that are involved in recognition of apoptotic cells (or
apoptotic bodies) by phagocytes (at least 10 recogni-
tion mechanisms have been identified so far)82.
Furthermore, phagocytosis of apoptotic cells has
been shown to be a highly regulatable process and
therefore likely to be amenable to pharmacological
manipulation83,84. It has been shown, for example,
that elevation of cAMP by PGs85 can downregulate
macrophage capacity to ingest apoptotic cells, whereas
treatment of phagocytes with glucocorticoids86,87, LXs59
or even certain cytokines88 can markedly increase
macrophage clearance of apoptotic cells. Interestingly,
the environment in which phagocytes are likely to
reside can also upregulate apoptotic-cell clearance.
For example, interactions with extracellular-matrix
components such as fibronectin89, and ligation of
macrophage CD44 with crosslinking antibodies90, can
augment the capacity of phagocytes to engulf apop-
totic cells. So, clearance of apoptotic cells in a non-
inflammatory manner by phagocytes is a therapeutic
possibility. Indeed, there is already evidence in animal
models that CD44 has an important role in resolving
lung inflammation91 and that glucocorticoids might exert
some of their therapeutic beneficial anti-inflammatory
effects in patients with asthma by influencing apoptosis
and apoptotic-cell clearance92. Some of these novel
developments have led to the design of drugs that have
even gone into clinical trials79,93.
cAMP
(Cyclic adenosine mono-
phosphate). A second messenger
system with inflammo-
modulatory properties.
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complexes such as p50–p50 homodimers, which might
antagonize NF-κB-dependent pro-inflammatory
gene expression while simultaneously promoting the
expression of genes that are required for the resolution
of inflammation. Broad-spectrum inhibitors of the
NF-κB pathway, such as antioxidants and proteasome
inhibitors, had the expected anti-inflammatory actions
during the initiation of inflammation. However, when
administered after the onset of inflammation, these
inhibitors prevented resolution, which was associated
with the inhibition of leukocyte apoptosis. We hypo-
thesize that this alternative NF-κB pathway promotes
leukocyte apoptosis through the recruitment of NF-κB
DNA-binding complexes that lack transactivation
domains and act as dominant-negative inhibitors of
anti-apoptotic gene expression (see FIG. 5). Indeed, the
persistence of p50–p50 homodimers during the reso-
lution of inflammation is perhaps not surprising con-
sidering the reported role of p50–p50 in the repression
of pro-inflammatory gene transcription106,107. Transgenic
mice that express p50 but not the inhibitory carboxyl
terminus of the p105 molecule showed increased
p50–p50 DNA-binding activity106. These mice show
reduced expression of cytokine genes in resident
macrophages and impaired leukocyte recruitment,
indicating p50-mediated suppression of inflammation
in vivo. These studies also revealed that in certain cell
types p50–p50 might enhance gene transcription, par-
ticularly when complexed with the IκB-like protein
BCL3. This might help explain the unlikely expression
of COX2 during resolution as RELA–p50 and p50–p50
complexes bind to distinct κB response elements in the
COX2 promoter, whereas the p50–p50 complex alone
can also upregulate COX2 transcription through asso-
ciation with transcriptional co-activators of the
C/EBP family.
These studies might also help explain, at the mole-
cular level, how NF-κB controls leukocyte clearance
during resolution. We found that inhibition of p105
processing to p50 and of NF-κB DNA-binding activ-
ity by the proteosome inhibitor MG132 reduced the
primary human CD4+ T cells in vitro103. We recently
described the induction of caspase-dependent apoptosis
in both PMN and eosinophil granulocytes by 15d-PGJ
2
through the inhibition of NF-κB independent of
PPARγ 32. Previous studies from our laboratory have also
shown that the specific inhibition of NF-κB can induce
granulocyte apoptosis directly and prevent the delay of
programmed cell death in cytokine-stimulated granulo-
cytes104.Although a direct causal link between 15d-PGJ
2
-
mediated inhibition of NF-κB and the resolution of
inflammation has yet to be proven, these studies show
that inhibiting NF-κB speeds up leukocyte apoptosis,
which is good news for resolution. This can be taken one
step forward by suggesting that selective inhibition of
leukocyte NF-κB in inflammatory disease processes
might also signal the onset of resolution.
In contrast to pharmacologically manipulating the
well-documented pro-inflammatory pathway of NF-κB
to control inflammation, we recently found that NF-κB
also has inherent anti-inflammatory properties that
mediate the resolution of acute experimental pleuritis105.
















Figure 5 | The profile of NF-κB subunit binding from onset to resolution in acute
inflammation. a | Inhibition of nuclear factor of κB (NF-κB) at the onset of the inflammatory
response resulted in the inhibition of acute inflammation due to the binding of the pro-
inflammatory NF-κB subunits p50/RELA. b | At resolution, however, there was predominance of
p50–p50 homodimers, which is responsible for pro-inflammatory mediator suppression and the
induction of pro-apoptotic gene expression leading to the onset of resolution (c). The inhibition of
NF-κB during this phase prevented resolution.
Box 3 | PPARγ-independent inhibitory effects of 15d-PGJ2 on NF-κB activation
Although 15d-PGJ
2
exerts some of its anti-inflammatory effects through peroxisome proliferator-activated receptor
gamma (PPARγ) activation, resulting in, for example, the inhibition of nuclear factor of κB (NF-κB) DNA binding15,
it seems that 15d-PGJ
2
has more of an effect on the inflammatory response by altering the activation of NF-κB directly.
Through Michael addition reactions, the highly reactive electrophilic carbon atom in the unsaturated carbonyl group of
the cyclopentane ring can react with nucleophiles, such as the free sulphydryl groups of glutathione (GSH) and cysteine
residues that form disulphide bonds in proteins17,148. In this respect, cyclopentenone PGs (cyPGs) can modify conserved
cysteine residues located in both the trans-acting DNA-binding proteins of NF-κB and elements of the upstream
signalling complex that activates NF-κB in response to pro-inflammatory cytokines (IκB kinase–IKK)17. Therefore,
15d-PGJ
2
can alkylate Cys179 of IKKβ, which is located in the kinase activation loop149. The DNA-binding subunits of
NF-κB, p50 and RELA might also be alkylated at Cys62 and Cys38, respectively, by 15dPGJ
2
(REF. 150). These residues are
located in the DNA-binding domains of the proteins and their alkylation prevents the activation of gene expression
representing multiple targets for the inactivation of NF-κB by 15d-PGJ
2
. It was shown recently that 15d-PGJ
2
was not
detectable during adipocyte differentiation, throughout the time course of LPS-administration to humans or in the
synovial fluid of arthritic patients, questioning the status of 15d-PGJ
2
as an endogenous PPARγ receptor ligand151.
However, given its short half-life and propensity to bind avidly to sulphydryl groups, one possible reason why 15d-PGJ
2
is not readily detectable in biological fluids is because it is bound to pro-inflammatory signalling proteins. Perhaps a
more appropriate strategy is to look for intracellular 15d-PGJ
2
/protein complexes.
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in certain disease processes. For instance, glucocorticoids
selectively induce eosinophil apoptosis and, like the
LXs, also enhance macrophage phagocytosis of apoptotic
bodies. This indicates that the role of steroids in the
treatment of chronic inflammation, such as asthma,
might be to reprogramme this ongoing inflammatory
lesion down a pro-resolution pathway.
It is now clear that the unbound glucocorticoid
receptor (GR) is associated within the cytoplasm in a
non-active oligomeric complex with regulatory pro-
teins such as heat-shock proteins 90 and 70, p59
immuno-philin and p23 phosphoprotein112. Receptor
engagement leads to GR activation, which occurs in at
least two distinct ways. Following ligand binding, the
GR undergoes a conformational change leading to
dissociation from specific proteins and the formation
of glucocorticoid/GR complex monomers or dimers.
In the latter case, the complex translocates into the
nucleus to control gene transcription. Monomer gluco-
corticoid/GR, however, might also regulate several
specific biochemical pathways, including the RELA
subunit of NF-κB and the JUN and FOS components
of AP1 (REFS 101,113–115) — so-called ‘non-genomic’
effects of glucocorticoids. This is an area of active
research for the identification of glucocorticoids with
distinct genomic versus non-genomic properties. No
studies have yet addressed the question of whether
these non-genomic actions of glucocorticoids can
‘modulate’ specific signal-transduction pathways that
favour resolution.
As well as binding to cytoplasmic steroid hormone
receptors, glucocorticoids also modulate the expression
and secretion of regulatory proteins that have anti-
inflammatory actions, of which the peptide annexin-1
(lipocortin-1) has been well described in vitro and 
in vivo116–119. Of a protein more than 300 amino-acids
long, small peptides drawn for the amino-terminal
region of annexin-1 retain biological activity. As the
annexin-1 amino terminus is not homologous to
other members of the family, it is likely that these pep-
tides reflect solely the biological effects of annexin-1
(REFS 41,120,121). The availability of a biologically active
peptide sequence could certainly be the starting point
for the development of new anti-inflammatory entities.
However, as small molecules are certainly more appeal-
ing for drug discovery, identification of the precise
target for anti-inflammatory actions of annexin-1 has
long been required. Recent data showed an unexpected
twist in this area, showing that annexin-1 and LXA
4
share the same ALX receptor122. Human recombinant
annexin-1 and annexin-1-derived peptides competed
with LXA
4
for receptor binding not only on engineered
cells but also on human PMNs. These results, and the
fact that the ALXR binds other endogenous proteins123
(including serum amyloid protein A), broadens our
understanding of the endogenous control of acute
inflammation by suggesting that this anti-inflammatory
receptor has been evolutionarily kept for multi-use,
that the ALXR is pivotal for controlling the inflammatory
response from start to finish and that the host econo-
mizes by using the same receptors with different agonists.
expression of the pro-apoptotic proteins BAX and p53 in
leukocytes during the resolution of acute inflammation105.
Finding BAX and p53 expressed during resolution in
this model is highly significant in itself as it identifies
the signalling pathways that mediate leukocyte apop-
tosis during acute resolution in vivo. Although the
BAX promoter contains both κB and p53 response
elements, BAX is thought to be a target gene for p53
rather than NF-κB. As p50–p50 homodimers are
known to positively regulate the p53 promoter, it is
interesting to speculate that p53 and NF-κB (p50–p50)
cooperate to regulate BAX expression and leucocyte
apoptosis during resolution, which would certainly
explain why p53 and BAX expression is diminished after
NF-κB inhibition during this period. Signal-induced
processing of p105 to p50 is dependent on inducible
phosphorylation and proteosome-mediated limited
proteolysis, which is dependent in turn on the IKK
complex. However, although the IKK complex is
essential for inducible p105 processing, IKKβ is redun-
dant in this pathway. It could be hypothesized that
endogenous anti-inflammatory mediators such as
cyPGs repress the activation of IKKβ, leading to a pre-
dominance of anti-inflammatory signalling pathways
that are regulated independently of IKK or by an alter-
native IKK complex that mediates p105 processing. It
should be noted that recent data with tissue-specific
knockout experiments of IKKβ have illustrated the
possible adverse side effects of global IKKβ inhibition108.
It was shown that inhibition of IKKβ expression in
colonic epithelial cells increases apoptosis in response
to ischaemia reperfusion injury, leading to a loss of
barrier function and considerable intestinal damage.
This indicates a tissue-specific role for IKKβ in inflam-
mation: IKKβ inhibition might reduce pro-inflammatory
cytokine production and leukocyte recruitment, and
inhibition of anti-apoptotic pathways might result in
increased tissue injury. This might be particularly
important in epithelial cells at mucosal surfaces that
have a barrier function, such as the lung and the
intestine. Understanding of these molecular mecha-
nisms that terminate pro-inflammatory signalling
pathways and promote the resolution of inflamma-
tion will enable the design and development of more
specific and appropriate pharmacological agents with
therapeutic potential for the treatment of chronic
inflammatory diseases.
Glucocorticoids and annexin
Glucocorticoids are endogenous potent anti-inflamma-
tory mediators that are released within minutes in
response to stress and tissue injury to control the
severity of the inflammatory response, functioning as
internal brakes against potentially exaggerated inflamma-
tory reactions mounted by the host109. Accordingly,
removal of this potent and primary braking mecha-
nism is associated with augmented and prolonged
inflammation, including, in some cases, lethality110,111.
Although probably not released into the circulation
during the resolution of acute inflammation, gluco-
corticoids might act, in part, by speeding up resolution
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mediators in a manner that might be related to pro-
resolution. These include methotrexate, sulphasalazine
and FK506, which are thought to exert their effects by
increasing adenosine release129. Adenosine works









, and generally signals
through the cAMP pathway to dampen inflammation130.
Methotrexate, for instance, is a widely used and highly
effective drug for the treatment of rheumatoid arthritis
and other inflammatory diseases. Data from in vitro
studies have shown that methotrexate increases adeno-
sine release from co-cultures of stimulated PMNs and
umbilical-vein endothelial cells or stimulated PMNs
and fibroblasts by inhi-bitingAICAR(5 aminoimida-
zole-4-carboxamidoribonucleotide) transformylase,
resulting in the accumulation of AICAR, which is the
nucleoside precursor that has previously been shown
to cause adenosine release from ischaemic cardiac
tissue131. Moreover, in vivo studies showed that adeno-
sine, working through the A
2
receptors, mediates the
anti-inflammatory effects of methotrexate in mice132,






sine fits well with our theme of resolution as it not only
prevents leukocyte trafficking but it might also switch
off acute inflammation by downregulating macrophage





development135. Therefore, adenosine or adenosine
receptor occupancy on cells of the immune system
presents a potential target for pro-resolving therapy,
with the exception of asthma and chronic obstructive
pulmonary disease in which there are continuously
high endogenous levels of adenosine, which has been
suggested to contribute to the chronic nature of the
disease136. Similar considerations, although not yet
supported by drugs in clinical use, could be put for-
ward for another family of five G-protein-coupled
receptors that signal through the cAMP — the
melanocortin receptors137. There are many chronic
inflammatory diseases (BOX 4) that could benefit from a
treatment regimen that, somehow, leads to resolution
of an ongoing inflammatory response. Drugs such as
methotrexate, sulphasalazine and FK506, which trigger
the synthesis of endogenous factors with established
anti-inflammatory and possibly pro-resolving proper-
ties, provide support for the concept of activating
pro-resolution pathways to treat chronic inflammation.
Future directions
Developing drugs based on endogenous mediators
that are inherent to resolution might represent a new
strategy in anti-inflammatory therapy. So far, a number
of factors have been identified, including the LXs and
the resolvins, which although are unstable with short
half-lives in vivo, exert powerful alleviating effects
when used in their native form or, particularly, as stable
analogues to treat experimental inflammatory diseases.
Therefore, the development of compliant mimetics
based on their structure shows great promise for clinical
usage. Indeed, efforts in LX research have identified
that the LX receptor, in addition to binding some of
In support of this, a distinct profile of endogenous
LXA
4
and annexin-1 generation was found in the cell-
free exudates of a mouse air-pouch model of resolving
inflammation, with LXA
4 
peaking at 4 hours but higher
annexin-1 levels detectable at 20 hours post-insult,
occurring at the same time as reduced PMN influx124.
Consistently, passive immunization of mice with neutral-
izing anti-annexin-1 sera did not exacerbate PMN
recruitment but prolonged it125. In this study, several
parameters of the acute inflammatory response were
altered by blockade of endogenous annexin-1,
including the profile of cytokine and proteolytic
enzyme release. The recent generation of annexin-1-
null mice confirm these findings. Several markers of
acute inflammation are exacerbated in these animals,
including the oedema (vascular) response and PMN
recruitment126. Annexin-1-null mice also have an
altered susceptibility of some of these inflammatory
responses to glucocorticoid treatment126. It is important
that similar observations have also been produced in a
model of chronic joint inflammation127, thereby high-
lighting potential therapeutic application of annexin-1
mimetics. So, the discovery that annexin-1 and its anti-
inflammatory peptido-mimetics bind to ALX can open
the way to the development of novel small-molecule
entities based on annexin-1 (REF. 128), thereby, at least in
part, retaining some of the anti-inflammatory properties
of glucocorticoids that signal the resolution of ongoing
inflammatory lesions.
Current drugs that may trigger resolution
To the author’s knowledge, there are no drugs in the clinic
that are purposefully based on the elicitation of pro-
resolving pathways, with the exception of those drugs that
target apoptosis93. There are, however, drugs in current
usage that mediate their effects, at least in part, by trigger-
ing the synthesis of endogenous anti-inflammatory
Box 4 | Examples of non-resolving inflammatory disease processes
This box includes known drugs that mediate some anti-inflammatory effects through
the induction of endogenous anti-inflammatory mediators. In doing so, they might
control ongoing inflammation by triggering resolution, a possibility that requires
further clarification. The shortness of this list reflects the scarcity of drugs developed






• Chronic granulomatous disease
• Psoriasis




• Drugs designed for the regulation of apoptosis (see REF. 93 for a detailed description of
the disease targets and mechanisms of action)
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for resolving inflammation as not all organs have the
same pro-resolving machinery. A good example of
this is in the kidney: a model of glomerulonephritis
showed that only a small percentage of influxing
PMNs are phagocytosed after undergoing apoptosis,
with most being cleared from the inflamed glomeruli
by returning to the circulation74. This indicates that
although the end result is resolution, the cellular mech-
anisms that ultimately switch off acute inflammation
might be organ specific.
Seminal work on the fate of inflammatory leuko-
cytes has revealed that not only is apoptosis of PMNs
and eosinophils crucial as a basic mechanism of cell
disposal, but that the apoptotic cells themselves express
on their surface a repertoire of signals, of which phos-
phatidylserine is well characterized138. These signals
facilitate their phagocytosis, and hence clearance, by
macrophages, while at the same time programming the
phagocytosing macrophage into an anti-inflammatory
or pro-resolution phenotype. Interestingly, rapid mem-
brane translocation of annexin-1 in T cells entering into
apoptosis also favours phagocytosis by macrophages
and other cleaning cells139. It is therefore not surprising
that injection of apoptotic PMNs or phosphatidylserine
the LX family of LOX/LOX interaction products, also
binds other endogenous factors, including the gluco-
corticoid-inducible annexin-1 (REF. 122). This has con-
sequences for understanding the nature of the
endogenous control of resolving inflammation, show-
ing how anti-inflammatory mediators of differing
structure and metabolic origin can exert their anti-
inflammatory effects through the same receptor. On
this theme, our ongoing challenge is to identify novel
receptors, the activation of which is integral to resolving
inflammation, thereby presenting alternative targets
for drug development128. Other potential pro-resolving
lipid mediators for drug targeting are PGD
2
metabo-
lites. We found a crucially important role for these
eicosanoids in controlling the severity and progres-
sion of an experimental T-lymphocyte-mediated
delayed-type hypersensitivity, indicating that stable
analogues of these eicosanoids might prove beneficial
in the management of certain immune-mediated dis-
eases, such as rheumatoid arthritis or encephalomyelitis.
However, as already mentioned, PGD
2
metabolites
seem to exacerbate allergic lung diseases, almost cer-
tainly indicating organ-specific pathways of inflamma-
tory resolution. This is important for drug development
Monocytes


























Figure 6 | A general schematic summarizing the mediators and mechanisms that drive and switch off acute innate
inflammation. During the early phases of acute inflammation and under the control of endogenous cytokines, chemokines,
cell-adhesion molecules and other pro-inflammatory stimuli, polymorphonuclear leukocytes (PMNs) or eosinophils (depending
on the nature of the stimulus) migrate into the inflamed site and, along with oedema, begin the task of neutralizing the injurious
agent. These leukocytes undergo apoptosis or programmed cell death, which, in vivo, can take from 24–48 hours for PMNs or
much longer for eosinophils. From our studies, it seems that BAX and p53 have a role in PMN apoptosis during resolution.
Within time (anything from 6–24 hours, depending again on the nature and ‘quantity’ of the stimulus), monocytes are recruited,
which differentiate to larger, more granular macrophages. These macrophages, which are generally fewer in number than the
PMN infiltrate, set about phagocytosing apoptotic PMNs or eosinophils. During this phase of active resolution, Reiter cells
(macrophages containing, usually, 2–4 effete leukocytes) can be observed histologically. When the apoptotic leukocytes are
cleared, macrophages must also be disposed of in order to prevent, for instance, granuloma tissue formation. The fate of
macrophages is either local-cell apoptosis or lymphatic drainage. The events controlling leukocyte apoptosis, phagocytosis
and macrophage clearance are not well understood, but it is known so far that the lipoxins, resolvins, annexin-1, PGD2
(prostaglandin D2) metabolites and nuclear factor of κB (NF-κB) subunits (p50–p50) are crucial in resolution.
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development of chronic inflammation and even
autoimmunity. We therefore suggest developing drugs
that mimic the actions of mediators that are essential
for resolution to treat chronic inflammatory diseases,
such as rheumatoid arthritis, asthma and encephalo-
myelitis, for example. Such therapeutics might be
based on the mechanisms of action of cyPGs, lipoxins
or lipoxin-receptor agonists, or on factors that trigger
leukocyte apoptosis and stimulate macrophage
phagocytosis of apoptotic cells. In doing so, it might
be possible to ‘trick’ ongoing inflammation into reso-
lution. Unfortunately, such therapeutics, with the
exception of those that regulate leukocyte apoptosis93,
are far from the clinic. This reflects the relative imma-
turity of this field of research. However, further 
investigation into the mediators and mechanisms 
that are central to resolution will bring us into a new
era of inflammation research, which, if approached
with creativity and persistence, might provide numer-
ous benefits for those suffering from inflammation-
mediated diseases.
liposomes in a model of peritonitis accelerates reso-
lution140 and a similar intervention inhibits onset of
experimental arthritis141. This could provide the
impetus to develop drugs that mimic the signals dis-
played by apoptosing cells and enhancing the capacity of
infiltrating or resident macrophages to phagocytose,
with the LXs and the glucocorticoids showing particular
effect in this area.As well as soluble mediators, the NF-κB
pathway has sprung some unexpected surprises —
namely, its role in pro-resolution through the preferential
binding of the p50–p50 anti-inflammatory subunits.
Understanding the signals that preferentially favour this
subunit complex formation will help in the develop-
ment of drugs that speed up resolution through the
induction of apoptosis. A temporal profile of the events
leading to resolution and mediators that control them,
as we understand them today, is shown in FIG. 6.
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